- Home
- BTU vs IBRX Comparison
BTU vs IBRX Comparison
Compare BTU & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTU
- IBRX
- Stock Information
- Founded
- BTU 2016
- IBRX 2014
- Country
- BTU United States
- IBRX United States
- Employees
- BTU N/A
- IBRX N/A
- Industry
- BTU Coal Mining
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTU Energy
- IBRX Health Care
- Exchange
- BTU Nasdaq
- IBRX Nasdaq
- Market Cap
- BTU 2.8B
- IBRX 2.4B
- IPO Year
- BTU N/A
- IBRX N/A
- Fundamental
- Price
- BTU $20.64
- IBRX $2.62
- Analyst Decision
- BTU Strong Buy
- IBRX Buy
- Analyst Count
- BTU 4
- IBRX 2
- Target Price
- BTU $29.00
- IBRX $17.38
- AVG Volume (30 Days)
- BTU 2.9M
- IBRX 6.1M
- Earning Date
- BTU 02-06-2025
- IBRX 11-12-2024
- Dividend Yield
- BTU 1.45%
- IBRX N/A
- EPS Growth
- BTU N/A
- IBRX N/A
- EPS
- BTU 3.78
- IBRX N/A
- Revenue
- BTU $4,348,600,000.00
- IBRX $7,332,000.00
- Revenue This Year
- BTU N/A
- IBRX $2,515.60
- Revenue Next Year
- BTU N/A
- IBRX $766.19
- P/E Ratio
- BTU $5.42
- IBRX N/A
- Revenue Growth
- BTU N/A
- IBRX 1218.71
- 52 Week Low
- BTU $20.21
- IBRX $2.61
- 52 Week High
- BTU $29.94
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- BTU 25.25
- IBRX 28.04
- Support Level
- BTU $20.95
- IBRX $2.61
- Resistance Level
- BTU $21.93
- IBRX $3.18
- Average True Range (ATR)
- BTU 0.72
- IBRX 0.28
- MACD
- BTU -0.14
- IBRX -0.20
- Stochastic Oscillator
- BTU 3.80
- IBRX 0.40
About BTU Peabody Energy Corporation
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. Powder River Basin segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan and other regions.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.